NEW YORK, NY / ACCESSWIRE / March 26, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Tupperware Brands Corporation (NYSE:TUP)

Investors Affected : January 30, 2019 – February 24, 2020

A class action has commenced on behalf of certain shareholders in Tupperware Brands Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Tupperware lacked effective internal controls; (2) as a result, Tupperware would need to investigate the accounting and liabilities of one of its brands, Fuller Mexico; (3) consequently, Tupperware would be unable to timely file its annual report on Form 10-K for its fiscal year 2019; (4) Tupperware did not properly account for its accounts payable and accrued liabilities at Fuller Mexico; (5) Tupperware provided overvalued earnings per share guidance; (6) Tupperware would need relief from its $650 million Credit Agreement; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/tupperware-brands-corporation-loss-submission-form/?id=5818&from=1

Tivity Health, Inc. (NASDAQ:TVTY)

Investors Affected : March 8, 2019 – February 19, 2020

A class action has commenced on behalf of certain shareholders in Tivity Health, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/tivity-health-inc-loss-submission-form/?id=5818&from=1

Becton Dickinson & Company (NYSE:BDX)

Investors Affected : November 5, 2019 – February 5, 2020

A class action has commenced on behalf of certain shareholders in Becton Dickinson & Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements;" (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/becton-dickinson-company-loss-submission-form/?id=5818&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 582699

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:ANAB).Investors who purchased AnaptysBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgadng.com/anab.

The investigation concerns whether AnaptysBio and certain of its officers and/or directors have violated federal securities laws.

On March 26, 2018, AnaptysBio announced data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Although the Company reported improvement among patients who received a single dose of etokimab compared to patients dosed with a placebo, later that day, an analyst from RBC Capital Markets issued a report that questioned the veracity of that data. On this news, AnaptysBio's stock price fell $6.31 per share, or 5.54%, to close at $107.52 per share on March 27, 2018. On August 27, 2018, AnaptysBio announced that it had deprioritized further clinical development of etokimab as a treatment for peanut allergy, but continued to tout the efficacy of etokimab in the treatment of atopic dermatitis, touting the purported "timeline and robustness" of a single dose of etokimab and describing the drug's treatment of patients in its Phase 2a clinical trial in this indication as a "truly remarkable result" with "widespread efficacy." However, on June 21, 2019, an analyst from Credit Suisse issued a report questioning the veracity of the Company's Phase 2a atopic dermatitis data, concluding that due to the study's small sample size and lack of critical details provided by the Company, "we must consider the possibility that the presence of rescue medications could have influenced the trial's response rates" and "we are now less certain about etokimab's efficacy profile." Accordingly, Credit Suisse downgraded AnaptysBio stock to neutral from outperform and slashed its price target to $79 from $137. On this news, AnaptysBio's stock price fell $7.78 per share, or 11.61%, to close at $59.24 per share on June 21, 2019. Finally, on November 8, 2019, AnaptysBio announced "very disappoint[ing]" data from its ATLAS trial, a Phase 2b multi-dose study which evaluated the efficacy of etokimab in patients with moderate-to-severe atopic dermatitis. Specifically, AnaptysBio revealed that each of the etokimab dosing arms "failed to meet the primary endpoint of the trial" and revealed that, as a result of this data, it had postponed the initiation of its Phase 2b etokimab clinical trial in asthma. On this news, AnaptysBio's stock price fell $25.98 per share, or 71.85%, to close at $10.18 per share on November 8, 2019.

If you are aware of any facts relating to this investigation, or purchased AnaptysBio shares, you can assist this investigation by visiting the firm's site: www.bgadng.com/anab. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 582698

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / Compare-autoinsurance.org (https://compare-autoinsurance.org/) is a top auto insurance brokerage website, providing car insurance quotes online from trustworthy agencies all over the United States. This website offers car insurance info about different coverage types, available discounts, and money-saving tips.

Car insurance agents are salesmen and their duty is to connect the potential customer to their respective insurance companies. Those who want to avoid dealing with the agent when buying car insurance, there is always the option of getting online quotes from https://compare-autoinsurance.org/.

Whenever working with an agent, it is important to ask the following:

If the policy covers the minimum state requirements. A good agent will have no problem providing this info. He will tell if the policyholder has the minimum coverage requirement. If not, the agent will recommend the client extra coverage.
Available discounts. The agent should be able to provide a list of all discounts offered by his representing company. He will also tell you more about the conditions needed
Electronic payment options. Allowing your carrier to get money from you each month is a great way to prevent coverage lapses.
What happens if the client is hit by an uninsured/underinsured driver? It is important to know if the client will be properly reimbursed, to cover the missing money for medical and repair bills.
How the company will handle an accident? Ask if the company will replace the damaged parts with new original manufacturer parts (OEM) or will opt for cheaper alternatives.

For additional info, money-saving tips and free car insurance quotes, visit https://compare-autoinsurance.org/.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

"Always ask your insurance agent more details about coverage levels, coverage options, extra services and claim handling," said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT:

Company Name: Internet Marketing Company
Person for contact: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org/

SOURCE: Internet Marketing Compan

ReleaseID: 582665

BOSTON, MA / ACCESSWIRE / March 26, 2020 / Thornton Law Firm LLP announces that a lawsuit has been filed against Tivity Health, Inc. on behalf of TVTY shareholders (NYSE:TVTY). Investors who purchased at least 1,000 shares of TVTY stock between March 8, 2019 and February 19, 2020 that are interested to learn more about the case and the lead plaintiff process, are encouraged to visit https://www.tenlaw.com/cases/TVTY. Shareholders may also contact Thornton Law Firm at shareholder@tenlaw.com, or call 617-531-3917.

Interested TVTY shareholders have until April 27, 2020, to apply to be lead plaintiff. The lawsuit alleges violations of the federal securities laws, and the class has not yet been certified. Until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. There is no minimum number of shares required to be a class member.

FOR MORE INFORMATION, VISIT: https://www.tenlaw.com/cases/TVTY.

According to the Complaint, Tivity Health, Inc. provides fitness and health improvement programs in the United States. The Company was formerly known as Healthways, Inc. and changed its name to Tivity Health Inc. in January 2017.

In December 2018, Tivity announced that it would acquire Nutrisystem, Inc., a provider of weight management products and services. On March 8, 2019, Tivity announced the completion of the Nutrisystem Acquisition for approximately $1.3 billion in cash and stock.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you have purchased at least 1,000 shares of TVTY stock (NYSE:TVTY), please contact the Thornton Law Firm's shareholder rights team at shareholder@tenlaw.com, or call 617-531-3917 to discuss the lead plaintiff process.

FOR MORE INFORMATION: https://www.tenlaw.com/cases/TVTY

Thornton Law Firm's securities attorneys are highly experienced in representing individual shareholders and institutional investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of shareholders. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:

Thornton Law Firm LLP
State Street Financial Center
1 Lincoln Street
Boston, MA 02111

SOURCE: Thornton Law Firm LLP

ReleaseID: 582697

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / In June, Thompson Education Center's CEO, Sherry Li, attended the Liberty High School Senior Assembly. Being a member of the Liberty Rotary Community, Ms. Li donated and presented scholarships to distinguished students. The Assembly was very well attended, with the Board of Education, Administration and Staff of Liberty Central Schools being present and who extended their best wishes to the students who have received awards as well as congratulated all the fellow graduating students for a job well done. Thompson Education Center is a project that plans to create a high-end education community in Sullivan County, Town of Thompson, covering 575 acres.

Thompson Education Center would work with accredited colleges and will include a Business School, a School of Film & Arts as well as programs in the following industries: Nursing/Medical Training, Culinary Arts, High School Equivalency and Executive and Vocational Training and related ancillary facilities. After completion of Phase 1, the project will include 4 classroom buildings, student dormitories, student townhouses, and a student center.

Currently, Thompson Education Center has entered into agreements and signed letter of interests with high schools, colleges, education institutions and systems both in U.S. and China, each of them will provide a great number of students to the center. Also, TEC has already been working with several U.S. accredited colleges on Undergraduate Programs and ESL Programs.

Economic growth within the local community is expected through the development of Thompson Education Center. Numerous construction professional firms have been retained for the project such as architects, engineers, land-use lawyers, local contractors. An increasing number of jobs will be created throughout the entire project, such as real estate agents, professors, instructors, librarian, cleaning, and maintenance workers amongst many others.

Thompson Education Center has already gained much support from local government agencies, small businesses and individuals. The center will continue working closely with Sullivan County Partnership, Chamber of Commerce, Visitors Association amongst others to bring more investors and visitors to Sullivan County to strengthen the economy. Thompson Education Center is proud to be a community member and eager to support its community and children. The center has been dedicated to delivering fresh fruits, vegetables, and meat to the Boys & Girls Club/Town of Wallkill, NY since late 2015.

Thompson Education Center – Dedicated to Education, Communications, and Business Opportunities: http://thompsoneducationcenterinitiatives.com/

Thompson Education Center and Sherry Li Appreciated by Catskill Regional Medical Center Foundation: https://finance.yahoo.com/news/thompson-education-center-sherry-li-004500936.html

Thompson Education Center and Sherry Li Invited to the Opening Ceremony of North America-China Dragon Business Association: https://finance.yahoo.com/news/thompson-education-center-sherry-li-034000392.html

Contact Information:

Thompson Education Center
Sherry Li
212-845-9519
ccoanys@yahoo.com

SOURCE: Thompson Education Center

ReleaseID: 582696

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Evotec SE (XETRA:EVT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 2:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60879

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582625

SOUDERTON, PA / ACCESSWIRE / March 26, 2020 / Ensuring a regular and quality blood supply is a constant challenge for healthcare systems worldwide. In the US, according to data from the American Red Cross, a mere 3% of citizens normally donate blood even though 38% of the population are eligible to donate; Every two seconds, someone requires a transfusion; And a single donation could save as many as three lives. The current US blood supplies can barely meet the needs of patients, many of whom rely on transfusions to survive, either because of severe trauma, life-threatening medical conditions, or surgical complications. In times of national emergencies, such as pandemics or major natural disasters, the lack of sufficient supplies can lead to unnecessary loss of life, exacerbating already tragic situations. Hence, the strong advocacy from the medical and scientific communities for the development and use of blood substitutes, such as the oxygen-carrying solution Hemopure, manufactured by Hemoglobin Oxygen Therapeutics, a clinical-stage biotech company headquartered in Souderton, PA.

While clinicians have been able to use evidence-based medical and surgical concepts to optimize hemostasis and minimize blood loss in an effort to improve patient outcomes, the number of donors over the past few years has dropped significantly, more than negating any savings. An additional risk, this time to the safety of US blood supply, is that despite what officials describe as near-Herculean efforts to screen donated blood for the emerging viruses, the nation's blood supply is not immune from contaminations as was the case a few years ago when the CDC announced that several cases of West Nile illness were attributed to blood transfusions that contained tainted blood.

The push to develop alternatives to traditional blood transfusions has intensified in the 21st century amidst the global population growth and aging, the emergence of new infectious agents, and the seemingly rising number of natural disasters due to climate change. Not only is the number of donors insufficient to meet demand, but the nature of blood is such that it cannot be readily stockpiled, as refrigerated blood has a shelf-life of only 42 days. With multiple positive medical journal articles already published on Hemopure, its characteristics – including no blood typing or cross matching as well as three-year stability without the need for refrigeration – are ideal for out-of-hospital applications and stockpiling for national emergencies. It is no surprise then that the US Department of Defense is funding a large prehospital clinical trial to evaluate use of Hemopure as a resuscitation fluid in conjunction with freeze-dried plasma.

Currently, Hemopure is stocked and used at several hospitals as an investigational product, under FDA's authorized expanded access protocols, for the treatment of severe anemia when blood transfusions are not an option. Interestingly, regulatory authorities in South Africa and Russia have already granted market approval for Hemopure for the treatment of perioperative anemia. "While blood transfusion will always be the gold standard of treatment, there is also an obvious need for alternative products, such as Hemopure, in our healthcare system and emergency preparedness," experts at BloodSupplySolution.com assert. "Stakeholders in government, academic medicine and industry should find a way to work together to make this happen proactively rather than reactively."

Blood Supply Solution – Oxygen-Carrying Blood Substitutes: http://bloodsupplysolution.com

Hemoglobin Oxygen Therapeutics LLC – https://hbo2therapeutics.com/

Expanded Access Protocol Using HBOC-201 – ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT02684474

Contact Information:

Gail Weiss
BloodSupplySolution.com
267-871-9577

gweiss@bloodsupplysolution.com
http://bloodsupplysolution.com

SOURCE: Hemopure

ReleaseID: 582693

BENSALEM, PA / ACCESSWIRE / March 26, 2020 / Law Offices of Howard G. Smith reminds investors of the upcoming May 11, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Funko, Inc. ("Funko" or the "Company") (NASDAQ:FNKO) securities between October 31, 2019 and March 5, 2020, inclusive (the "Class Period").

Investors suffering losses on their Funko investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On February 5, 2020, after the market closed, Funko issued a press release announcing preliminary fourth quarter 2019 financial results. Therein, Funko stated that "[n]et sales are expected to be approximately $214 million, a decrease of 8% compared to $233 million in the fourth quarter of 2018."

On this news, the Company's share price fell $6.20, or over 40%, to close at $9.29 per share on February 6, 2020, thereby injuring investors.

On March 5, 2020, after the market closed, Funko issued a press release announcing its fourth quarter and full year 2019 financial results. Therein, Funko affirmed that net sales for fourth quarter had decreased 4% year-over-year to $213.6 million due to, among other things, "softness at retail during the holiday season which led to a decrease in orders."

On this news, Funko's share price fell $0.32, or over 4%, to close at $6.92 on March 6, 2020, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Funko was experiencing lower than expected sales; (2) that, as a result, Funko was reasonably likely to incur a writedown for slower moving inventory; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

If you purchased Funko securities during the Class Period, you may move the Court no later than May 11, 2020 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

SOURCE: Law Offices of Howard G. Smith

ReleaseID: 582551

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 5, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Tilray, Inc. ("Tilray" or "the Company") (NASDAQ:TLRY) investors who purchased securities between January 15, 2019 and March 2, 2020, inclusive (the "Class Period").

If you suffered a loss on your Tilray investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information here or contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, via email shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights.

On March 2, 2020 Tilray announced its financial results for the fourth quarter and full year 2019. For the year, the Company reported a net loss of $321.2 million, compared to a net loss of $67.7 million the previous year. Moreover, Tilray "recorded non-cash charges of $112.1 million related to impairment of the Authentic Brands Group LLC (‘ABG') agreement as well as $68.6 million in inventory reserves."

On this news, the Company's share price fell $2.33, or over 15%, to close at $13.02 per share on March 3, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the purported advantages of the ABG Agreement were significantly overstated; (2) that the underperformance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired Tilray securities during the Class Period, you may move the Court no later than May 5, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

SOURCE: Glancy Prongay & Murray LLP

ReleaseID: 582549

Erongo gold project covers 606 km2 in the Navachab-Otjikoto gold belt in proximity to Osino Resources Twin Hills gold discovery

Priority target area underlain by favourable stratigraphy and structures identified at Twin Hills

Soil geochemical survey has collected 2,500 samples covering 30% of priority target area, analyses pending; additional sampling planned

Company continues to monitor and manage Namibian responses to Covid-19 and announces planned changes in senior management

HALIFAX, NS / ACCESSWIRE / March 26, 2020 / Namibia Critical Metals Inc. ("Namibia Critical Metals" or the "Company") (TSXV:NMI) today provided an update on progress of exploration on its Erongo Gold Project (EPL 6440 "Erongo") located near the town of Karibib in central Namibia. Erongo is one of three prospective gold projects in the company's portfolio within the emerging gold belt which hosts the Navachab and Otjikoto gold mines (Figure 1). The Company is undertaking a regional geochemical soil survey at Erongo to assess the potential for the discovery of orogenic/hydrothermal gold deposits similar to the nearby Navachab Gold Mine which is operated by QKR and the Twin Hills discovery of Osino Resources Corp. ("Osino").

The Erongo Gold Project comprises 606 square kilometers situated 20 kilometers north of the Navachab gold mine and 10 kilometers northwest of the Twin Hills discovery (Figure 2). The project area is centered on the Erongo granitic intrusive complex which was emplaced into the older metasedimentary rocks of the Damaran orogeny which host the gold mineralization of interest at Navachab, Twin Hills and at the Otjikoto gold mine operated by B2 Gold which is located 230 kilometers to the northeast.

Don Burton, President of Namibia Critical Metals stated, "Most investor attention is understandably focused on our heavy rare earth project at Lofdal where we have recently entered into a joint venture with the Japan Oil, Gas and Metals National Corporation ("JOGMEC"). However, an important aspect of the Company's assets lies in the diversity of the commodities within our portfolio. Given the increasing recognition of the significance of Namibia's emerging gold belt, it is an appropriate moment to direct more attention to the gold potential in our Erongo, Otjiwarongo and Grootfontein projects."

Erongo Gold Exploration Program

The area of interest at Erongo lies along the northern limb of the Krantzberg anticline and is underlain by metasedimentary rocks equivalent to the stratigraphy noted on the southern limb of the anticline at Twin Hills, with associated structural features defined by airborne magnetics (Figure 2). The area is largely covered by aeolian sands and/or calcrete with very little outcrop. As Osino has successfully demonstrated, gold mineralization can be detected by surficial geochemical sampling (soils and calcrete) in this environment. The discovery at Twin Hills was announced in August 2019 (Osino Resources company press release August 26, 2019) and Osino is working towards development of a maiden resource estimate as part of a 20,000 meter drill program.

The Company has collected 2,500 soil samples to date on a systematic grid with a line spacing of 200 meters and sample spacing of 100 meters over the central sector of the priority area (Figure 2). These samples cover roughly 30% of the area of interest. Samples will be sieved and analyzed by handheld XRF over the next 3-4 weeks prior to submission for gold analysis. Selected samples will then be analyzed for gold using low level detection limits (down to 0.2 ppb Au) to define areas of interest. Results from gold analyzes are therefore expected in mid-May and continuing sample coverage is planned to progress to the south.

Impact of Covid-19 to Operations

The Company continues to closely monitor recommendations from Namibian health authorities and the World Health Organization concerning the mitigation of the Covid-19 pandemic. Current restrictions by the Namibian health authorities are being respected with regards to operations in the Khomas and Erongo Regions (encompassing the Windhoek-Swakopmund corridor) where travel restrictions have been implemented. This has affected continued field activity at Erongo for the time being however operations at Lofdal in the Kunene Region are continuing. The Company has completed the first four drill holes at Lofdal and expects to report on first results in April.

Planned Changes in Management

The Company also announced today that Pine van Wyk will be stepping down as CEO of the Company at the end of his current contract term on May 31, 2020. Donald Burton, the current President of the Company will assume the responsibilities previously undertaken by Mr. van Wyk. Mr. van Wyk will be available to the Company on a consultancy basis after May 31 to ensure a seamless transition of responsibilities.

Donald M. Burton, P.Geo. and President of Namibia Critical Metals Inc., is the Company's Qualified Person and has reviewed and approved this press release.

Figure 1 – Location of Namibia Critical Metals' projects highlighting position of gold projects (Erongo, Otjiwarongo and Grootfontein) in relation to important gold projects within the Navachab-Otjikoto gold belt

Figure 2 – Erongo Gold Project (EPL 6440) showing area of priority soil sampling over meta-sediments on northern flank of Krantzberg anticline. Twin Hills gold discovery in meta-sediments on southern flank of anticline. Airborne magnetics in background is analytic signal response from government survey by Geological Survey of Namibia.

About Namibia Critical Metals Inc.

Namibia Critical Metals Inc. holds a diversified portfolio of exploration and advanced stage projects in the country of Namibia focused on the development of sustainable and ethical sources of metals for the battery, electric vehicle and associated industries. The Company also has significant land positions in areas favourable for gold mineralization.

The Lofdal Heavy Rare Earth Project is the Company's most advanced project having completed a Preliminary Economic Assessment in 2014 and full Environmental Impact Assessment in 2017. An application has been made for a mining licence at Lofdal. The project is now in joint venture with JOGMEC who are funding the current $3,000,000 drilling and metallurgical program with the object of doubling the resource size and optimization of the process flow sheet.

At the Erongo Gold Project, stratigraphic equivalents to the sediments hosting the recent Osino gold discovery at Twin Hills have been identified but not yet sampled. Detailed soil surveys are planned over this highly prospective area.

The Epembe Tantalum-Niobium Project is also at an advanced stage with a well-defined, 10 km long carbonatite dyke that has been delineated by detailed mapping with over 11,000 meters of drilling. Preliminary mineralogical and metallurgical studies including sorting tests (XRT), indicate the potential for significant physical upgrading. Further work will be undertaken to advance the project to a preliminary economic assessment stage.

The Kunene Cobalt-Copper Project comprises a very large area of favorable stratigraphy ("the DOF") along strike to the west of the Opuwo Co-Cu-Zn deposit. Secondary copper mineralization over a wide area points to preliminary evidence of a regional-scale hydrothermal system. Exploration targets on EPLs held in the Kunene project comprise direct extensions of the DOF style mineralization to the west, sediment-hosted cobalt and copper, orogenic copper, and stratabound Mn and Zn-Pb mineralization.

Earlier stage projects include the Grootfontein Project which has potential for magmatic Cu-Ni mineralization, Mississippi Valley-type Zn-Pb-V mineralization and Otjikoto-style gold mineralization.

The common shares of Namibia Critical Metals Inc. trade on the TSX Venture Exchange under the symbol "NMI".

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information please contact –

Namibia Critical Metals Inc.

Don Burton, President
Tel: +01 (902) 835-8760
Fax: +01 (902) 835-8761
Email: Info@NamibiaREE.com
Web site: www.NamibiaCriticalMetals.com

The foregoing information may contain forward-looking information relating to the future performance of Namibia Rare Earths Inc. Forward-looking information, specifically, that concerning future performance, is subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions.

SOURCE: Namibia Critical Metals Inc.

ReleaseID: 582689